<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02019394</url>
  </required_header>
  <id_info>
    <org_study_id>14915A</org_study_id>
    <secondary_id>2012-005646-37</secondary_id>
    <nct_id>NCT02019394</nct_id>
  </id_info>
  <brief_title>Absolute Bioavailability of Lu AE58054 in Healthy Subjects</brief_title>
  <official_title>Interventional, Open-label Study Investigating the Absolute Bioavailability of Lu AE58054 After Multiple Oral Dosing and a Single Radio-labelled Intravenous Micro-dose as Well as the Contribution of Cytochrome P450 2D6 to the Exposure of Lu AE58054 in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the absolute bioavailability of the Lu AE58054 tablet formulation at steady
      state
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute bioavailability: (AUC0-24) Dose oral/(AUC0-inf) Dose IV</measure>
    <time_frame>Day 10</time_frame>
    <description>Intravenous (IV)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ratio of (AUC0-24(PM)/AUC0-24(EM))</measure>
    <time_frame>Day 10</time_frame>
    <description>Poor Metaboliser (PM); Extensive Metaboliser (EM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number and frequency of adverse events</measure>
    <time_frame>Up to Day 16</time_frame>
    <description>Standard clinical safety assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>Up to Day 16</time_frame>
    <description>Adverse event monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk of Suicidality</measure>
    <time_frame>Up to Day 16</time_frame>
    <description>Columbia Suicide Severity Rating Scale (C-SSRS) categorisation based on Columbia Classification Algorithm of Suicide Assessment (C-CASA) definitions</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Lu AE58054</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lu AE58054</intervention_name>
    <description>Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.
Intravenous dosing: 90 Î¼g/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10.</description>
    <arm_group_label>Lu AE58054</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy men and women aged between 21-55 years (inclusive) and with an BMI in the
             range 18.5 to 32 kg/m2 (minimum weight 60 kg for men and 55 kg for women).

          -  The subjects CYP2D6 genotype must be determined before inclusion into the study.

          -  Women must not be pregnant or lactating.

        Exclusion Criteria:

          -  The subject is, in the opinion of the investigator, unlikely to comply with the
             protocol or is unsuitable for any reason.

        Other inclusion and exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GB803</name>
      <address>
        <city>Nottingham</city>
        <zip>NG11 6JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>December 18, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2013</study_first_posted>
  <last_update_submitted>March 20, 2014</last_update_submitted>
  <last_update_submitted_qc>March 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

